Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Numerous obstacles stand in the way of ending the hepatitis B and C virus (HBV/HCV) epidemics in the United States.
Consuming coffee, even decaf, could protect against non-alcoholic fatty liver disease (NAFLD), according to a mouse study.
Generic versions of major hepatitis C drugs are apparently very effective.
Gilead’s experimental hepatitis C treatment for all genotypes boasted a high success rate among those treated for the first time.
U.S. guidelines for hepatitis C testing may miss up to a quarter of cases, according to new research.
Researchers are launching trials of a $300 generic hepatitis C regimen that could help expand treatment of the virus in poorer nations.
People who receive hepatitis C treatment from community-based treatment providers are cured at the same rate as those who see specialists.
People with hepatitis C do just as well with a liver transplant that is infected with the virus as those receiving an uninfected organ.
There is a possible association between hepatitis C virus (HCV) and head and neck cancers.
Having resistance to a particular class of hepatitis C drugs does not affect the likelihood of a cure with AbbVie’s Viekira Pak.
Researchers have developed a new algorithm to predict who will benefit from intensive care unit treatment of end-stage liver disease.
Gilead's tenofovir alafenamide (TAF) combats hepatitis B comparably to and is safer than Viread (tenofovir disoproxil fumarate, or TDF).
Western European men who have sex with men who have HIV and are cured of hepatitis C virus are reinfected with HCV at a very high rate.
AbbVie’s hepatitis C virus (HCV) regimen Viekira Pak boasted excellent safety and efficacy data in a large, ongoing, real-world trial.
People retreated for hepatitis C virus after a failed cure attempt have a very good chance of achieving a cure.
Those who treat their hepatitis C while they have compensated cirrhosis increase their survival rate to that of the general population